195 related articles for article (PubMed ID: 32594155)
1. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment.
de Nie I; de Blok CJM; van der Sluis TM; Barbé E; Pigot GLS; Wiepjes CM; Nota NM; van Mello NM; Valkenburg NE; Huirne J; Gooren LJG; van Moorselaar RJA; Dreijerink KMA; den Heijer M
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3293-9. PubMed ID: 32594155
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.
de Blok CJM; Wiepjes CM; Nota NM; van Engelen K; Adank MA; Dreijerink KMA; Barbé E; Konings IRHM; den Heijer M
BMJ; 2019 May; 365():l1652. PubMed ID: 31088823
[TBL] [Abstract][Full Text] [Related]
3. Skin cancer incidence in transgender individuals receiving gender-affirming hormone treatment: a nationwide cohort study in the Netherlands.
Rahmat A; De Nie I; Wiepjes CM; Den Heijer M; Rustemeyer T; De Blok CJM; Dreijerink KMA
Int J Dermatol; 2023 Jul; 62(7):882-887. PubMed ID: 37140088
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens.
Gooren L; Morgentaler A
Andrologia; 2014 Dec; 46(10):1156-60. PubMed ID: 24329588
[TBL] [Abstract][Full Text] [Related]
5. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226
[TBL] [Abstract][Full Text] [Related]
6. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.
Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M
J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731
[TBL] [Abstract][Full Text] [Related]
7. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment.
de Blok CJM; Dijkman BAM; Wiepjes CM; Staphorsius AS; Timmermans FW; Smit JM; Dreijerink KMA; den Heijer M
J Clin Endocrinol Metab; 2021 Jan; 106(2):e782-e790. PubMed ID: 33206172
[TBL] [Abstract][Full Text] [Related]
8. Transition memories: experiences of trans adult women with hormone therapy and their beliefs on the usage of hormone blockers to suppress puberty.
Giovanardi G; Morales P; Mirabella M; Fortunato A; Chianura L; Speranza AM; Lingiardi V
J Endocrinol Invest; 2019 Oct; 42(10):1231-1240. PubMed ID: 30953318
[TBL] [Abstract][Full Text] [Related]
9. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets.
Wiepjes CM; Nota NM; de Blok CJM; Klaver M; de Vries ALC; Wensing-Kruger SA; de Jongh RT; Bouman MB; Steensma TD; Cohen-Kettenis P; Gooren LJG; Kreukels BPC; den Heijer M
J Sex Med; 2018 Apr; 15(4):582-590. PubMed ID: 29463477
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
11. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.
de Blok CJ; Wiepjes CM; van Velzen DM; Staphorsius AS; Nota NM; Gooren LJ; Kreukels BP; den Heijer M
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):663-670. PubMed ID: 34481559
[TBL] [Abstract][Full Text] [Related]
12. Incidence of testicular cancer in trans women using gender-affirming hormonal treatment: a nationwide cohort study.
de Nie I; Wiepjes CM; de Blok CJM; van Moorselaar RJA; Pigot GLS; van der Sluis TM; Barbé E; van der Voorn P; van Mello NM; Huirne J; den Heijer M
BJU Int; 2022 Apr; 129(4):491-497. PubMed ID: 34390620
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
14. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
15. [Treating transgender minors with hormones: obstacles in medical ethics today].
Bernier A; Leplège A
Med Sci (Paris); 2018; 34(6-7):595-598. PubMed ID: 30067215
[No Abstract] [Full Text] [Related]
16. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.
Glintborg D; T'Sjoen G; Ravn P; Andersen MS
Eur J Endocrinol; 2021 Jun; 185(2):R49-R63. PubMed ID: 34081614
[TBL] [Abstract][Full Text] [Related]
17. Oestrogen and anti-androgen therapy for transgender women.
Tangpricha V; den Heijer M
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):291-300. PubMed ID: 27916515
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
19. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
20. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
